Am J Emerg Med:创伤性颅内出血预后不良的相关因素

2017-04-22 MedSci MedSci原创

轻度创伤性脑损伤(mTBI)患者合并颅内损伤,或复杂mTBI恶化的风险较高。不同机构间不同患者的临床管理不同。研究者进行探索性分析,确定哪些患者不太可能有不利预后,减少重症护理可能是未来的目标。这个单中心回顾性队列研究纳入2001年1月到2010年12月间的因mTBI急诊就诊的患者。格拉斯哥昏迷评分(GCS)为15,初始头颅CT存在创伤性异常,并在24小时内重复头颅CT符合。两周内死亡、两周内神经

轻度创伤性脑损伤(mTBI)患者合并颅内损伤,或复杂mTBI恶化的风险较高。不同机构间不同患者的临床管理不同。

研究者进行探索性分析,确定哪些患者不太可能有不利预后,减少重症护理可能是未来的目标。

这个单中心回顾性队列研究纳入2001年1月到2010年12月间的因mTBI急诊就诊的患者。
格拉斯哥昏迷评分(GCS)为15,初始头颅CT存在创伤性异常,并在24小时内重复头颅CT符合。两周内死亡、两周内神经外科手术、住院超过48h、复查头颅CT加重为综合不良结局。应用分类回归树的方法确定与不良后果相关的因素。

1011例患者在24小时内进行两次头颅CT扫描,240(24%)例患者存在复杂mTBI且GCS 为15。其中,56(23%)例发生综合不良预后。年龄,头痛,蛛网膜下腔出血这三项危险因素,可准确判断 93%的患者存在预后不良。

研究结果显示复杂mTBI且GCS 15分患者不良结局相关的三个因素。没有这些风险因素,明不良后果的风险低,并可能表明病人出院回家是安全的。将这项研究结果应用于临床实践可能需要更多的研究。



本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2025445, encodeId=ef98202544591, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu Mar 01 00:02:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335135, encodeId=7b8f133513586, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457461, encodeId=c18d145e4611d, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488333, encodeId=0082148833397, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607425, encodeId=b439160e42582, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2018-03-01 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=2025445, encodeId=ef98202544591, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu Mar 01 00:02:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335135, encodeId=7b8f133513586, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457461, encodeId=c18d145e4611d, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488333, encodeId=0082148833397, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607425, encodeId=b439160e42582, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-23 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=2025445, encodeId=ef98202544591, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu Mar 01 00:02:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335135, encodeId=7b8f133513586, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457461, encodeId=c18d145e4611d, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488333, encodeId=0082148833397, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607425, encodeId=b439160e42582, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2025445, encodeId=ef98202544591, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu Mar 01 00:02:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335135, encodeId=7b8f133513586, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457461, encodeId=c18d145e4611d, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488333, encodeId=0082148833397, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607425, encodeId=b439160e42582, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2025445, encodeId=ef98202544591, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Thu Mar 01 00:02:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335135, encodeId=7b8f133513586, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457461, encodeId=c18d145e4611d, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488333, encodeId=0082148833397, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607425, encodeId=b439160e42582, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 23:02:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]

相关资讯

2016APTA建议——中度到重度创伤性脑损伤患者结局评价发布

2016年8月,美国物理治疗协会(APTA)神经物理治疗分会TBIEDGE工作组发布了中度到重度创伤性脑损伤患者结局评价建议,该工作组建议为临床医生,研究人员以及教育工作组选择结局评价措施提供指导。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载)

EBioMedicine:创伤性脑损伤能够损害上百种基因,导致严重脑部疾病

在一项新的研究中,美国加州大学洛杉矶分校的研究人员报道,头部损伤能够损害大脑中的上百种基因,从而增加人们患上很多种神经系统疾病和精神疾病的风险。相关研究结果发表在2017年2月的EBioMedicine期刊上,论文标题为“Traumatic Brain Injury Induces Genom

Crit Care Med:创伤性脑损伤可以影响心脏收缩功能

此前有研究表明,创伤性脑损伤可能会影响心脏功能。近期,一项发表在杂志Crit Care Med上的研究旨在确定中重度创伤性脑损伤患者发生收缩功能障碍的频率、进程和入院的危险因素。此项研究为前瞻性队列研究。在中重度创伤性脑损伤后1天内和第1周内进行经胸超声心动图检查;轻度创伤性脑损伤后1天内进行经胸超声心动图(对照组)。通过经胸超声心动图评估心脏收缩功能,收缩功能障碍定义为射血分数小于25%。多变量

Crit Care Med:研究者发现创伤性脑损伤恢复的新预测因素

在预测创伤性脑损伤恢复方面,外伤性遗忘症比最初的格拉斯哥昏迷评分更优,但是需要花费更长时间来评估(几天或几周)。 我们在一级创伤ICU进行了两阶段队列研究,旨在探究,视觉固定(入住ICU 24小时内更高认知功能的标志物)的恢复能否作为创伤性脑损伤恢复的早期指标。 研究纳入了2010年至2013年的中度至重型颅脑损伤患者。对181例失去固定能力的患者进行了视觉固定评估(通过标准化

PLOS Med:儿童期创伤性脑损伤会导致长期的健康问题

近期有数据显示,儿童期创伤性脑损伤与长期的健康问题具有潜联系。研究人员进一步得出结论,应该对儿童和青少年制定年龄特异性的临床指导方针和预防策略。 来自牛津大学的Amir Sariaslan博士和同事们对1985-1973年之间的1143470名参与者(来自瑞典出生队列)进行了研究,探究儿童期创伤性脑损伤、成人死亡率、精神病发病率和社会结果之间的关联。最终研究者纳入了104290名在≤25岁时

Neurosurgery:扩散张量成像:严重创伤性脑损伤和动脉瘤性蛛网膜下腔出血的可能生物标志物?

背景:需要一个能够更好地描述创伤性脑损伤(TBI)和动脉瘤性蛛网膜下腔出血(aSAH)的进程,且作为临床研究的早期指标的生物标志物。扩散张量成像(DTI)在TBI中研究较多,但是在aSAH中的研究较少。目的:探讨全脑DTI成像作为TBI和aSAH的生物标志物及早期指标的可行性。方法:43例重型颅脑损伤患者(n = 20)或aSAH(N = 23)纳入一项前瞻性、观察性、综合监测研究中,22例患者(